Global Dyslipidemia Epidemiology and Patient Flow Analysis - 2012

Fore Pharma, October 2012, Pages: 24

Fore Pharma announced the results of its Dyslipidemia patient population study in a new report ‘Global Dyslipidemia Epidemiology and Patient Flow Analysis - 2012’. The report provides insights into Dyslipidemia epidemiology, Dyslipidemia diagnosed patients, and Dyslipidemia treatment rate for top seven pharmaceutical markets. The study measures key indicators such as prevalence of Dyslipidemia derived from epidemiological analysis, percentage of patients diagnosed with Dyslipidemia, and percentage of patients treated with Dyslipidemia therapy.

The study helps executives estimate Dyslipidemia market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.

The report provides estimates and forecasts of Dyslipidemia prevalence, Dyslipidemia diagnosis rate, and Dyslipidemia treatment rate for the period 2012-2019. The information is presented by leading geographies including the US, Germany, France, Spain, Italy, UK, and Japan. The study design is based on collection and interpretation of data from registries, scientific journals and literatures, government databases and other secondary sources.

Key Features of the Report:
- Dyslipidemia: Disease Definition
- Dyslipidemia Patient Flow
- Dyslipidemia Prevalence
- Dyslipidemia Diagnosed Patients
- Dyslipidemia Treated Patients

1. Dyslipidemia: Disease Definition
2. Global Dyslipidemia Patient Flow
2A. Global Dyslipidemia Prevalence
2B. Global Dyslipidemia Diagnosed Patients
2C. Global Dyslipidemia Treated Patients
3. Dyslipidemia Patient Flow in the US
3A. Dyslipidemia Prevalence in the US
3B. Dyslipidemia Diagnosed Patients in the US
3C. Dyslipidemia Treated Patients in the US
4. Dyslipidemia Patient Flow in Europe
4A. Dyslipidemia Prevalence in Europe
4B. Dyslipidemia Diagnosed Patients in Europe
4C. Dyslipidemia Treated Patients in Europe
5. Dyslipidemia Patient Flow in Germany
5A. Dyslipidemia Prevalence in Germany
5B. Dyslipidemia Diagnosed Patients in Germany
5C. Dyslipidemia Treated Patients in Germany
6. Dyslipidemia Patient Flow in France
6A. Dyslipidemia Prevalence in France
6B. Dyslipidemia Diagnosed Patients in France
6C. Dyslipidemia Treated Patients in France
7. Dyslipidemia Patient Flow in Spain
7A. Dyslipidemia Prevalence in Spain
7B. Dyslipidemia Diagnosed Patients in Spain
7C. Dyslipidemia Treated Patients in Spain
8. Dyslipidemia Patient Flow in Italy
8A. Dyslipidemia Prevalence in Italy
8B. Dyslipidemia Diagnosed Patients in Italy
8C. Dyslipidemia Treated Patients in Italy
9. Dyslipidemia Patient Flow in UK
9A. Dyslipidemia Prevalence in UK
9B. Dyslipidemia Diagnosed Patients in UK
9C. Dyslipidemia Treated Patients in UK
10. Dyslipidemia Patient Flow in Japan
10A. Dyslipidemia Prevalence in Japan
10B. Dyslipidemia Diagnosed Patients in Japan
10C. Dyslipidemia Treated Patients in Japan
11. Appendix
12. Research Methodology
12A. Sources

Table 1: Global Dyslipidemia Patient Flow (2012)
Table 2: Global Dyslipidemia Patient Flow Forecast (2012-2019)
Table 3: Dyslipidemia Patient Flow in the US (2012)
Table 4: Dyslipidemia Patient Flow Forecast in the US (2012-2019)
Table 5: Dyslipidemia Patient Flow in Europe (2012)
Table 6: Dyslipidemia Patient Flow Forecast in Europe (2012-2019)
Table 7: Dyslipidemia Patient Flow in Germany (2012)
Table 8: Dyslipidemia Patient Flow Forecast in Germany (2012-2019)
Table 9: Dyslipidemia Patient Flow in France (2012)
Table 10: Dyslipidemia Patient Flow Forecast in France (2012-2019)
Table 11: Dyslipidemia Patient Flow in Spain (2012)
Table 12: Dyslipidemia Patient Flow Forecast in Spain (2012-2019)
Table 13: Dyslipidemia Patient Flow in Italy (2012)
Table 14: Dyslipidemia Patient Flow Forecast in Italy (2012-2019)
Table 15: Dyslipidemia Patient Flow in UK (2012)
Table 16: Dyslipidemia Patient Flow Forecast in UK (2012-2019)
Table 17: Dyslipidemia Patient Flow in Japan (2012)
Table 18: Dyslipidemia Patient Flow Forecast in Japan (2012-2019)

Figure 1: Global Dyslipidemia Patient Flow (2012)
Figure 2: Global Dyslipidemia Patient Flow Forecast (2012-2019)
Figure 3: Dyslipidemia Patient Flow in the US (2012)
Figure 4: Dyslipidemia Patient Flow Forecast in the US (2012-2019)
Figure 5: Dyslipidemia Patient Flow in Europe (2012)
Figure 6: Dyslipidemia Patient Flow Forecast in Europe (2012-2019)
Figure 7: Dyslipidemia Patient Flow in Germany (2012)
Figure 8: Dyslipidemia Patient Flow Forecast in Germany (2012-2019)
Figure 9: Dyslipidemia Patient Flow in France (2012)
Figure 10: Dyslipidemia Patient Flow Forecast in France (2012-2019)
Figure 11: Dyslipidemia Patient Flow in Spain (2012)
Figure 12: Dyslipidemia Patient Flow Forecast in Spain (2012-2019)
Figure 13: Dyslipidemia Patient Flow in Italy (2012)
Figure 14: Dyslipidemia Patient Flow Forecast in Italy (2012-2019)
Figure 15: Dyslipidemia Patient Flow in UK (2012)
Figure 16: Dyslipidemia Patient Flow Forecast in UK (2012-2019)
Figure 17: Dyslipidemia Patient Flow in Japan (2012)
Figure 18: Dyslipidemia Patient Flow Forecast in Japan (2012-2019)

Customers who bought this item also bought

• Epidemiology: Dyslipidemia - Undertreated and underdiagnosed pandemic
• Global Dyslipidemia Drug Pipeline Capsule - 2012
• Epidemiology: Dyslipidemia
• The Pricing and Reimbursement Environment for Metabolic Disease Therapies
• Medical Nutrition - A Global Market Overview
• Disinfectants - Global Strategic Business Report
• Wheelchairs (Powered and Manual) - Global Strategic Business Report
• Minimally Invasive BPH and Prostate Cancer Treatment Devices Markets Worldwide
• Monolithic Ceramics Applications - A Global Market Overview
• Medical Ceramics - Global Market Overview